Escherichia coli sequence type 131: Epidemiology and challenges in treatment

Expert Review of Anti-Infective Therapy

Volumn 12, Issue 5, 2014, Pages 597-609

  Qureshi, Zubair A ^a   Doi, Yohei ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

community associated infection; epidemiology; Escherichia coli; extended spectrum lactamase; fluoroquinolone resistance; healthcare associated infection; risk factor; ST131; urinary tract infection

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIMETHATE; COTRIMOXAZOLE; DORIPENEM; DOXYCYCLINE; ERTAPENEM; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; MINOCYCLINE; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; PIVMECILLINAM; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; ANTIINFECTIVE AGENT; BETA LACTAMASE; PENICILLANIC ACID; PIPERACILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BACTERIUM DETECTION; BACTERIUM ISOLATE; CYSTITIS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI ST131; HUMAN; NONHUMAN; PREVALENCE; REVIEW; RISK FACTOR; SEPSIS; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; DRUG EFFECTS; ENZYMOLOGY; EPIDEMIOLOGY; ESCHERICHIA COLI INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; UNITED STATES;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; CEPHALOSPORINS; CYSTITIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; SEPSIS; UNITED STATES;

EID: 84899009317     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2014.899901     Document Type: Review

References (121)

1. Pitout JD. Extraintestinal pathogenic Escherichia coli: a combination of virulence with antibiotic resistance. Front Microbiol 2012;3:9
2. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002; 113(Suppl 1A):5S-13S
3. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U. S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012;56(4): 2181-3
4. Zilberberg MD, Shorr AF. Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000-2009. Infect Control Hosp Epidemiol 2013;34(9):940-6
5. Johnson JR, Johnston B, Clabots C, et al. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010;51(3):286-94
6. Vimont S, Boyd A, Bleibtreu A, et al. The CTX-M-15-producing Escherichia coli clone O25b: H4-ST131 has high intestine colonization and urinary tract infection abilities. PLoS One 2012;7(9)e46547
7. Wirth T, Falush D, Lan R, et al. Sex and virulence in Escherichia coli: an evolutionary perspective. Mol Microbiol 2006;60(5): 1136-51
8. Jaureguy F, Landraud L, Passet V, et al. Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains. BMC Genomics 2008;9:560
9. Clermont O, Dhanji H, Upton M, et al. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTXM- 15-producing strains. J Antimicrob Chemother 2009;64(2):274-7
10. Dhanji H, Doumith M, Clermont O, et al. Real-time PCR for detection of the O25b-ST131 clone of Escherichia coli and its CTX-M-15-like extended-spectrum b-lactamases. Int J Antimicrob Agents 2010; 36(4):355-8
11. Johnson JR, Menard M, Johnston B, et al. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antimicrob Agents Chemother 2009;53(7): 2733-9
12. Matsumura Y, Yamamoto M, Nagao M, et al. Detection of extended-spectrum b-lactamase-producing Escherichia coli ST131 and ST405 clonal groups by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol 2014. [Epub ahead of print]
13. Nielsen JB, Albayati A, Jorgensen RL, et al. An abbreviated MLVA identifies Escherichia coli ST131 as the major extended-spectrum b-lactamase-producing lineage in the Copenhagen area. Eur J Clin Microbiol Infect Dis 2013;32(3):431-6
14. Coque TM, Novais A, Carattoli A, et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum b-lactamase CTX-M-15. Emerg Infect Dis 2008;14(2):195-200
15. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, et al. Intercontinental emergence of Escherichia coli clone O25:H4- ST131 producing CTX-M-15. J Antimicrob Chemother 2008;61(2):273-81
16. Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M b-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents 2010;35(4):316-21
17. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011;66(1):1-14
18. Jones GL, Warren RE, Skidmore SJ, et al. Prevalence and distribution of plasmid-mediated quinolone resistance genes in clinical isolates of Escherichia coli lacking extended-spectrum b-lactamases. J Antimicrob Chemother 2008;62(6): 1245-51
19. Cagnacci S, Gualco L, Debbia E, et al. European emergence of ciprofloxacinresistant Escherichia coli clonal groups O25: H4-ST 131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. J Clin Microbiol 2008;46(8):2605-12
20. Uchida Y, Mochimaru T, Morokuma Y, et al. Clonal spread in Eastern Asia of ciprofloxacin-resistant Escherichia coli serogroup O25 strains, and associated virulence factors. Int J Antimicrob Agents 2010;35(5):444-50
21. Johnson JR, Tchesnokova V, Johnston B, et al. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis 2013;207(6): 919-28
22. Dahbi G, Mora A, Lopez C, et al. Emergence of new variants of ST131 clonal group among extraintestinal pathogenic Escherichia coli producing extended-spectrum b-lactamases. Int J Antimicrob Agents 2013;42(4):347-51
23. Matsumura Y, Yamamoto M, Nagao M, et al. Emergence and spread of B2-ST131- O25b, B2-ST131-O16 and D-ST405 clonal groups among extended-spectrum-blactamase- producing Escherichia coli in Japan. J Antimicrob Chemother 2012; 67(11):2612-20
24. Doi Y, Park YS, Rivera JI, et al. Community-associated extended-spectrum b-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis 2013;56(5):641-8
25. Chung HC, Lai CH, Lin JN, et al. Bacteremia caused by extended-spectrumb- lactamase-producing Escherichia coli sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. Antimicrob Agents Chemother 2012;56(2):618-22
26. Lo'pez-Cerero L, Navarro MD, Bellido M, et al. Escherichia coli belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. J Antimicrob Chemother 2014;69(3):809-14
27. Price LB, Johnson JR, Aziz M, et al. The epidemic of extended-spectrum-b- lactamaseproducing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. mBio 2013;4(6)e00377-13
28. Banerjee R, Robicsek A, Kuskowski MA, et al. Molecular epidemiology of Escherichia coli sequence type 131 and Its H30 and H30-Rx subclones among extendedspectrum- b-lactamase-positive and -negative E. coli clinical isolates from the Chicago Region, 2007 to 2010. Antimicrob Agents Chemother 2013;57(12):6385-8
29. Suzuki S, Shibata N, Yamane K, et al. Change in the prevalence of extendedspectrum- b-lactamase-producing Escherichia coli in Japan by clonal spread. J Antimicrob Chemother 2009;63(1):72-9
30. Arpin C, Quentin C, Grobost F, et al. Nationwide survey of extended-spectrum b-lactamase-producing Enterobacteriaceae in the French community setting. J Antimicrob Chemother 2009;63(6):1205-14
31. Sidjabat HE, Derrington P, Nimmo GR, Paterson DL. Escherichia coli ST131 producing CTX-M-15 in Australia. J Antimicrob Chemother 2010;65(6):1301-3
32. Naseer U, Haldorsen B, Simonsen GS, Sundsfjord A. Sporadic occurrence of CMY-2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway. Clin Microbiol Infect 2010;16(2):171-8
33. Johnson JR, Urban C, Weissman SJ, et al. Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25: H4) and blaCTX-M-15 among extendedspectrum- b-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother 2012;56(5): 2364-70
34. Peirano G, Sang JH, Pitondo-Silva A, et al. Molecular epidemiology of extendedspectrum- b-lactamase-producing Klebsiella pneumoniae over a 10 year period in Calgary, Canada. J Antimicrob Chemother 2012;67(5):1114-20
35. Karfunkel D, Carmeli Y, Chmelnitsky I, et al. The emergence and dissemination of CTX-M-producing Escherichia coli sequence type 131 causing community-onset bacteremia in Israel. Eur J Clin Microbiol Infect Dis 2013;32(4):513-21
36. Denisuik AJ, Lagace-Wiens PR, Pitout JD, et al. Molecular epidemiology of extended-spectrum b-lactamase-, AmpC b-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother 2013;68(Suppl 1): i57-65
37. Coelho A, Mora A, Mamani R, et al. Spread of Escherichia coli O25b:H4-B2- ST131 producing CTX-M-15 and SHV-12 with high virulence gene content in Barcelona (Spain). J Antimicrob Chemother 2011;66(3):517-26
38. Xu L, Shabir S, Bodah T, et al. Regional survey of CTX-M-type extended-spectrum b-lactamases among Enterobacteriaceae reveals marked heterogeneity in the distribution of the ST131 clone. J Antimicrob Chemother 2011;66(3):505-11
39. Hrabak J, Empel J, Bergerova T, et al. International clones of Klebsiella pneumoniae and Escherichia coli with extended-spectrum b-lactamases in a Czech hospital. J Clin Microbiol 2009;47(10):3353-7
40. Yumuk Z, Afacan G, Nicolas-Chanoine MH, et al. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. J Antimicrob Chemother 2008;62(2):284-8
41. Yano H, Uemura M, Endo S, et al. Molecular characteristics of extendedspectrum b-lactamases in clinical isolates from Escherichia coli at a Japanese tertiary hospital. PLoS One 2013;8(5)e64359
42. Hussain A, Ewers C, Nandanwar N, et al. Multiresistant uropathogenic Escherichia coli from a region in India where urinary tract infections are endemic: genotypic and phenotypic characteristics of sequence type 131 isolates of the CTX-M-15 extended-spectrum-b-lactamaseproducing lineage. Antimicrob Agents Chemother 2012;56(12):6358-65
43. Brolund A, Edquist PJ, Makitalo B, et al. Epidemiology of extended-spectrum b-lactamase-producing Escherichia coli in Sweden 2007-2011. Clin Microbiol Infect 2013. [Epub ahead of print]
44. Kudinha T, Johnson JR, Andrew SD, et al. Escherichia coli sequence type 131 as a prominent cause of antibiotic resistance among urinary Escherichia coli isolates from reproductive-age women. J Clin Microbiol 2013;51(10):3270-6
45. Reyna-Flores F, Barrios H, Garza-Ramos U, et al. Molecular epidemiology of Escherichia coli O25b-ST131 isolates causing community-acquired UTIs in Mexico. Diagn Microbiol Infect Dis 2013;76(3): 396-8
46. Peirano G, van der Bij AK, Gregson DB, Pitout JD. Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum b-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol 2012;50(2):294-9
47. Courpon-Claudinon A, Lefort A, Panhard X, et al. Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features. Clin Microbiol Infect 2011;17(4): 557-65
48. Ha YE, Kang CI, Cha MK, et al. Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum b-lactamase-producing Escherichia coli in patients with cancer. Int J Antimicrob Agents 2013;42(5):403-9
49. Brisse S, Diancourt L, Laouenan C, et al. Phylogenetic distribution of CTX-M- and non-extended-spectrum-b-lactamaseproducing Escherichia coli isolates: group B2 isolates, except clone ST131, rarely produce CTX-M enzymes. J Clin Microbiol 2012;50(9):2974-81
50. Banerjee R, Johnston B, Lohse C, et al. The clonal distribution and diversity of extraintestinal Escherichia coli isolates vary according to patient characteristics. Antimicrob Agents Chemother 2013;57(12): 5912-17
51. Blanco J, Mora A, Mamani R, et al. National survey of Escherichia coli causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4- B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. J Antimicrob Chemother 2011;66(9):2011-21
52. Banerjee R, Strahilevitz J, Johnson JR, et al. Predictors and molecular epidemiology of community-onset extended-spectrum b-lactamase-producing Escherichia coli infection in a Midwestern Community. Infect Control Hosp Epidemiol 2013;34(9): 947-53
53. Colpan A, Johnston B, Porter S, et al. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrugresistant pathogen among US veterans. Clin Infect Dis 2013;57(9):1256-65
54. Adams-Sapper S, Diep BA, Perdreau-Remington F, Riley LW. Clonal composition and community clustering of drug-susceptible and -resistant Escherichia coli isolates from bloodstream infections. Antimicrob Agents Chemother 2013;57(1): 490-7
55. Freeman JT, McBride SJ, Heffernan H, et al. Community-onset genitourinary tract infection due to CTX-M-15-producing Escherichia coli among travelers to the Indian subcontinent in New Zealand. Clin Infect Dis 2008;47(5):689-92
56. Tangden T, Cars O, Melhus A, Lowdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum b-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother 2010;54(9):3564-8
57. Laupland KB, Church DL, Vidakovich J, et al. Community-onset extended-spectrum b-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect 2008;57(6):441-8
58. Pitout JD, Campbell L, Church DL, et al. Molecular characteristics of travel-related extended-spectrum-b-lactamase-producing Escherichia coli isolates from the Calgary Health Region. Antimicrob Agents Chemother 2009;53(6):2539-43
59. Peirano G, Laupland KB, Gregson DB, Pitout JD. Colonization of returning travelers with CTX-M-producing Escherichia coli. J Travel Med 2011;18(5):299-303
60. Rogers BA, Kennedy KJ, Sidjabat HE, et al. Prolonged carriage of resistant E. coli by returned travellers: clonality, risk factors and bacterial characteristics. Eur J Clin Microbiol Infect Dis 2012;31(9):2413-20
61. Nicolas-Chanoine MH, Robert J, Vigan M, et al. Different factors associated with CTX-M-producing ST131 and non-ST131 Escherichia coli clinical isolates. PLoS One 2013;8(9)e72191
62. Ewers C, Grobbel M, Stamm I, et al. Emergence of human pandemic O25: H4-ST131 CTX-M-15 extended-spectrumb- lactamase-producing Escherichia coli among companion animals. J Antimicrob Chemother 2010;65(4):651-60
63. Platell JL, Cobbold RN, Johnson JR, et al. Commonality among fluoroquinoloneresistant sequence type ST131 extraintestinal Escherichia coli isolates from humans and companion animals in Australia. Antimicrob Agents Chemother 2011;55(8):3782-7
64. Harada K, Nakai Y, Kataoka Y. Mechanisms of resistance to cephalosporin and emergence of O25b-ST131 clone harboring CTX-M-27 b-lactamase in extraintestinal pathogenic Escherichia coli from dogs and cats in Japan. Microbiol Immunol 2012;56(7):480-5
65. Johnson JR, Miller S, Johnston B, et al. Sharing of Escherichia coli sequence type ST131 and other multidrug-resistant and urovirulent E. coli strains among dogs and cats within a household. J Clin Microbiol 2009;47(11):3721-5
66. Huber H, Zweifel C, Wittenbrink MM, Stephan R. ESBL-producing uropathogenic Escherichia coli isolated from dogs and cats in Switzerland. Vet Microbiol 2013; 162(2-4):992-6
67. Tamang MD, Nam HM, Jang GC, et al. Molecular characterization of extendedspectrum- b-lactamase-producing and plasmid-mediated AmpC b-lactamase-producing Escherichia coli isolated from stray dogs in South Korea. Antimicrob Agents Chemother 2012;56(5): 2705-12
68. Dierikx CM, van Duijkeren E, Schoormans AH, et al. Occurrence and characteristics of extended-spectrum-blactamase- and AmpC-producing clinical isolates derived from companion animals and horses. J Antimicrob Chemother 2012; 67(6):1368-74
69. Wu G, Day MJ, Mafura MT, et al. Comparative analysis of ESBL-positive Escherichia coli isolates from animals and humans from the UK, The Netherlands and Germany. PLoS One 2013;8(9)e75392
70. Randall LP, Clouting C, Horton RA, et al. Prevalence of Escherichia coli carrying extended-spectrum b-lactamases (CTX-M and TEM-52) from broiler chickens and turkeys in Great Britain between 2006 and 2009. J Antimicrob Chemother 2011;66(1): 86-95
71. Cortes P, Blanc V, Mora A, et al. Isolation and characterization of potentially pathogenic antimicrobial-resistant Escherichia coli strains from chicken and pig farms in Spain. Appl Environ Microbiol 2010;76(9): 2799-805
72. Mora A, Herrera A, Mamani R, et al. Recent emergence of clonal group O25b: K1:H4-B2-ST131 ibeA strains among Escherichia coli poultry isolates, including CTX-M-9-producing strains, and comparison with clinical human isolates. Appl Environ Microbiol 2010;76(21): 6991-7
73. Dahmen S, Metayer V, Gay E, et al. Characterization of extended-spectrum b-lactamase (ESBL)-carrying plasmids and clones of Enterobacteriaceae causing cattle mastitis in France. Vet Microbiol 2013; 162(2-4):793-9
74. Hordijk J, Wagenaar JA, van de Giessen A, et al. Increasing prevalence and diversity of ESBL/AmpC-type b-lactamase genes in Escherichia coli isolated from veal calves from 1997 to 2010. J Antimicrob Chemother 2013;68(9):1970-3
75. Overdevest I, Willemsen I, Rijnsburger M, et al. Extended-spectrum b-lactamase genes of Escherichia coli in chicken meat and humans, The Netherlands. Emerg Infect Dis 2011;17(7):1216-22
76. Madec JY, Poirel L, Saras E, et al. Non-ST131 Escherichia coli from cattle harbouring human-like blaCTX-M-15-carrying plasmids. J Antimicrob Chemother 2012; 67(3):578-81
77. Zheng H, Zeng Z, Chen S, et al. Prevalence and characterisation of CTX-M b-lactamases amongst Escherichia coli isolates from healthy food animals in China. Int J Antimicrob Agents 2012;39(4):305-10
78. Leverstein-van Hall MA, Dierikx CM, Cohen Stuart J, et al. Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains. Clin Microbiol Infect 2011;17(6):873-80
79. Banerjee R, Johnston B, Lohse C, et al. Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. Infect Control Hosp Epidemiol 2013; 34(4):361-9
80. Liss MA, Peterson EM, Johnston B, et al. Prevalence of ST131 among fluoroquinolone-resistant Escherichia coli obtained from rectal swabs before transrectal prostate biopsy. Urology 2013;81(3):548-55
81. Kim B, Kim J, Seo MR, et al. Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea. Infection 2013; 41(3):603-12
82. Ender PT, Gajanana D, Johnston B, et al. Transmission of an extended-spectrum-blactamase- producing Escherichia coli (sequence type ST131) strain between a father and daughter resulting in septic shock and emphysematous pyelonephritis. J Clin Microbiol 2009;47(11):3780-2
83. Kudinha T, Johnson JR, Andrew SD, et al. Distribution of phylogenetic groups, sequence type ST131, and virulenceassociated traits among Escherichia coli isolates from men with pyelonephritis or cystitis and healthy controls. Clin Microbiol Infect 2013;19(4)e173-80
84. Kang CI, Cha MK, Kim SH, et al. Clinical and molecular epidemiology of community-onset bacteremia caused by extended-spectrum b-lactamase-producing Escherichia coli over a 6-year period. J Korean Med Sci 2013;28(7):998-1004
85. Pitout JD, Gregson DB, Campbell L, Laupland KB. Molecular characteristics of extended-spectrum-b-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. J Antimicrob Chemother 2009;53(7): 2846-51
86. Johnson JR, Johnston B, Clabots C, et al. Escherichia coli sequence type ST131 as an emerging fluoroquinolone-resistant uropathogen among renal transplant recipients. Antimicrob Agents Chemother 2010;54(1):546-50
87. Bert F, Johnson JR, Ouattara B, et al. Genetic diversity and virulence profiles of Escherichia coli isolates causing spontaneous bacterial peritonitis and bacteremia in patients with cirrhosis. J Clin Microbiol 2010;48(8):2709-14
88. Williamson DA, Freeman JT, Porter S, et al. Clinical and molecular correlates of virulence in Escherichia coli causing bloodstream infection following transrectal ultrasound-guided (TRUS) prostate biopsy. J Antimicrob Chemother 2013;68(12): 2898-906
89. Assimacopoulos A, Johnston B, Clabots C, Johnson Jr. Post-prostate biopsy infection with Escherichia coli ST131 leading to epididymo-orchitis and meningitis caused by Gram-negative bacilli. J Clin Microbiol 2012;50(12):4157-9
90. Vigil KJ, Johnson JR, Johnston BD, et al. Escherichia coli pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis 2010;50(3):374-80
91. Weissman SJ, Adler A, Qin X, Zerr DM. Emergence of extended-spectrum b-lactam resistance among Escherichia coli at a US academic children's hospital is clonal at the sequence type level for CTX-M-15, but not for CMY-2. Int J Antimicrob Agents 2013; 41(5):414-20
92. Chandramohan L, Revell PA. Prevalence and molecular characterization of extendedspectrum- b-lactamase-producing Enterobacteriaceae in a pediatric patient population. Antimicrob Agents Chemother 2012;56(9):4765-70
93. Johnson JR, Anderson JT, Clabots C, et al. Within-household sharing of a fluoroquinolone-resistant Escherichia coli sequence type ST131 strain causing pediatric osteoarticular infection. Pediatr Infect Dis J 2010;29(5):473-5
94. Chmielarczyk A, Pobiega M, Wojkowska-Mach J, et al. Molecular epidemiology, plasmid analysis, virulence, and resistance of Escherichia coli isolated from neonatal intensive care units in Poland. Diagn Microbiol Infect Dis 2013; 76(4):542-5
95. Oteo J, Cercenado E, Fernandez-Romero S, et al. Extended-spectrum-b- lactamaseproducing Escherichia coli as a cause of pediatric infections: report of a neonatal intensive care unit outbreak due to a CTX-M-14-producing strain. Antimicrob Agents Chemother 2012;56(1):54-8
96. Birgy A, Mariani-Kurkdjian P, Bidet P, et al. Characterization of extendedspectrum- b-lactamase-producing Escherichia coli strains involved in maternal-fetal colonization: prevalence of E. coli ST131. J Clin Microbiol 2013;51(6):1727-32
97. Lee MY, Choi HJ, Choi JY, et al. Dissemination of ST131 and ST393 community-onset, ciprofloxacin-resistant Escherichia coli clones causing urinary tract infections in Korea. J Infect 2010;60(2):146-53
98. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52(5): e103-20
99. Johnson JR, Drawz SM, Porter S, Kuskowski MA. Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and coresistance phenotype among recent Escherichia coli isolates from U.S. veterans. Antimicrob Agents Chemother 2013;57(10):4856-60
100. Karlowsky JA, Denisuik AJ, Lagace-Wiens PR, et al. In vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD Surveillance Study. Antimicrob Agents Chemother 2014;58(2):1252-6
101. Oteo J, Orden B, Bautista V, et al. CTXM- 15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother 2009;64(4):712-17
102. Dewar S, Reed LC, Koerner RJ. Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. J Antimicrob Chemother 2014;69(2):303-8
103. Jansaker F, Frimodt-Moller N, Sjogren I, Dahl Knudsen J. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections. J Antimicrob Chemother 2014;69(3):769-72
104. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extendedspectrum b-lactamases (ESBLs). Clin Microbiol Infect 2000;6(9):460-3
105. Rodriguez-Bano J, Navarro MD, Retamar P. Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa/Grupo de Estudio de Infeccion Hospitalaria Group. b-Lactam/b-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum b-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54(2):167-174
106. Lopez-Cerero L, Bellido Mdel M, Serrano L, et al. Escherichia coli O25b:H4/ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance. Enferm Infecc Microbiol Clin 2013;31(6): 385-8
107. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012;56(4):2108-13
108. Qureshi ZA, Paterson DL, Peleg AY, et al. Clinical characteristics of bacteraemia caused by extended-spectrum b-lactamaseproducing Enterobacteriaceae in the era of CTX-M-type and KPC-type b-lactamases. Clin Microbiol Infect 2012;18(9):887-93
109. Naas T, Cuzon G, Gaillot O, et al. When carbapenem-hydrolyzing b-lactamase KPC meets Escherichia coli ST131 in France. Antimicrob Agents Chemother 2011;55(10): 4933-4
110. Morris D, Boyle F, Ludden C, et al. Production of KPC-2 carbapenemase by an Escherichia coli clinical isolate belonging to the international ST131 clone. Antimicrob Agents Chemother 2011;55(10):4935-6
111. Mantengoli E, Luzzaro F, Pecile P, et al. Escherichia coli ST131 producing extended-spectrum b-lactamases plus VIM-1 carbapenemase: further narrowing of treatment options. Clin Infect Dis 2011; 52(5):690-1
112. Kim YA, Qureshi ZA, Adams-Haduch JM, et al. Features of infections due to Klebsiella pneumoniae carbapenemase-producing Escherichia coli: emergence of sequence type 131. Clin Infect Dis 2012;55(2): 224-31
113. Cai JC, Zhang R, Hu YY, et al. Emergence of Escherichia coli sequence type 131 isolates producing KPC-2 carbapenemase in China. Antimicrob Agents Chemother 2014;58(2): 1146-52
114. Karlowsky JA, Adam HJ, Baxter MR, et al. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study. Antimicrob Agents Chemother 2013; 57(11):5600-11
115. Wiskirchen DE, Crandon JL, Furtado GH, et al. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-blactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011;55(7): 3220-5
116. Castanheira M, Farrell SE, Krause KM, et al. Contemporary diversity of b-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent b-lactamase groups. Antimicrob Agents Chemother 2014;58(2):833-8
117. Galani I, Souli M, Daikos GL, et al. Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece. J Chemother 2012;24(4):191-4
118. Pouillot F, Chomton M, Blois H, et al. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother 2012;56(7):3568-75
119. Totsika M, Kostakioti M, Hannan TJ, et al. A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. J Infect Dis 2013; 208(6):921-8
120. Moriel DG, Schembri MA. Vaccination approaches for the prevention of urinary tract infection. Curr Pharm Biotechnol 2014;14(11):967-74
121. Morosini MI, Garcia-Castillo M, Coque TM, et al. Antibiotic coresistance in extended-spectrum-b-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006;50(8):2695-9